These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 27155613)

  • 1. Phase 1 study on S-1 and oxaliplatin therapy as an adjuvant after hepatectomy for colorectal liver metastases.
    Takahashi M; Hasegawa K; Oba M; Saiura A; Arita J; Sakamoto Y; Shinozaki E; Mizunuma N; Matsuyama Y; Kokudo N
    Invest New Drugs; 2016 Aug; 34(4):468-73. PubMed ID: 27155613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
    Park SR; Hong YS; Lim HS; Seong MW; Kong SY; Kim SY; Park YI; Jung KH
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):953-64. PubMed ID: 23982118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter randomized phase II study on S-1 and oxaliplatin therapy as an adjuvant after hepatectomy for colorectal liver metastases (YCOG1001).
    Ozawa M; Watanabe J; Ishibe A; Goto K; Fujii Y; Nakagawa K; Suwa Y; Suwa H; Masui H; Sugita M; Mochizuki Y; Yamagishi S; Hasegawa S; Homma Y; Momiyama M; Kumamoto T; Matsuyama R; Takeda K; Taguri M; Endo I
    Cancer Chemother Pharmacol; 2024 Jun; 93(6):565-573. PubMed ID: 38374403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy.
    Shin SJ; Jung M; Jeung HC; Kim HR; Rha SY; Roh JK; Chung HC; Ahn JB
    Invest New Drugs; 2012 Aug; 30(4):1501-10. PubMed ID: 21567184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of irinotecan/S-1 combination chemotherapy for patients with oxaliplatin-refractory colorectal cancer.
    Oh SY; Ju YT; Choi SK; Ha CY; Lee WS; Kim HG; Lee GW; Kwon HC; Kang JH
    Invest New Drugs; 2011 Oct; 29(5):1050-6. PubMed ID: 20238142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I trial of S-1 with oxaliplatin in patients with relapsed and metastatic colorectal cancer.
    Kim HS; Park MJ; Uhm JE; Lee Y; Lee HY; Kang EM; Lee J; Park SH; Park JO; Lim HY; Kang WK; Park YS
    Int J Colorectal Dis; 2009 Nov; 24(11):1311-6. PubMed ID: 19609538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancer.
    Kim SY; Hong YS; Kim BC; Park JW; Choi HS; Jeong SY; Kim DY; Hong CW; Sohn DK; Jung KH
    Invest New Drugs; 2009 Jun; 27(3):269-74. PubMed ID: 18815728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer.
    Takahara N; Isayama H; Nakai Y; Sasaki T; Hamada T; Uchino R; Mizuno S; Miyabayashi K; Kogure H; Yamamoto N; Sasahira N; Hirano K; Ijichi H; Tateishi K; Tada M; Koike K
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):985-90. PubMed ID: 23995699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I dose-escalating study of S-1 in combination with oxaliplatin for patients with advanced and/or metastatic colorectal cancer.
    Li J; Yin J; Zhu X; Liu Y; Cao J; Lu F; Zuo Y
    Anticancer Drugs; 2008 Aug; 19(7):745-8. PubMed ID: 18594218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
    Hong YS; Park YS; Lim HY; Lee J; Kim TW; Kim KP; Kim SY; Baek JY; Kim JH; Lee KW; Chung IJ; Cho SH; Lee KH; Shin SJ; Kang HJ; Shin DB; Jo SJ; Lee JW
    Lancet Oncol; 2012 Nov; 13(11):1125-32. PubMed ID: 23062232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9.
    Winther SB; Österlund P; Berglund Å; Glimelius B; Qvortrup C; Sorbye H; Pfeiffer P;
    BMC Cancer; 2017 Aug; 17(1):548. PubMed ID: 28814275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer.
    Yamada Y; Higuchi K; Nishikawa K; Gotoh M; Fuse N; Sugimoto N; Nishina T; Amagai K; Chin K; Niwa Y; Tsuji A; Imamura H; Tsuda M; Yasui H; Fujii H; Yamaguchi K; Yasui H; Hironaka S; Shimada K; Miwa H; Hamada C; Hyodo I
    Ann Oncol; 2015 Jan; 26(1):141-148. PubMed ID: 25316259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I Study of Neoadjuvant Chemotherapy with Capecitabine and Oxaliplatin for Locally Advanced Gastric Cancer.
    Satake H; Kondo M; Mizumoto M; Kotake T; Okita Y; Ogata T; Hatachi Y; Yasui H; Miki A; Imai Y; Ichikawa C; Murotani K; Kotaka M; Kato T; Kaihara S; Tsuji A
    Anticancer Res; 2017 Jul; 37(7):3703-3710. PubMed ID: 28668863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety Analysis of Oxaliplatin-based Chemotherapy for Advanced Gastric Cancer.
    Inadomi K; Kusaba H; Matsushita Y; Tanaka R; Mitsugi K; Arimizu K; Hirano G; Makiyama A; Ohmura H; Uchino K; Hanamura F; Shibata Y; Kuwayama M; Esaki T; Takayoshi K; Arita S; Ariyama H; Akashi K; Baba E
    Anticancer Res; 2017 May; 37(5):2663-2671. PubMed ID: 28476842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
    Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
    Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modified FOLFOX6 with oxaliplatin stop-and-go strategy and oral S-1 maintenance therapy in advanced colorectal cancer: CCOG-0704 study.
    Nakayama G; Kodera Y; Yokoyama H; Okuda N; Watanabe T; Tanaka C; Iwata N; Ohashi N; Koike M; Fujiwara M; Nakao A
    Int J Clin Oncol; 2011 Oct; 16(5):506-11. PubMed ID: 21431344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of S-1 in colorectal cancer.
    Miyamoto Y; Sakamoto Y; Yoshida N; Baba H
    Expert Opin Pharmacother; 2014 Aug; 15(12):1761-70. PubMed ID: 25032886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of 3-weekly combination chemotherapy using epirubicin, oxaliplatin, and S-1 (EOS) in patients with previously untreated advanced gastric cancer.
    Sym SJ; Hong J; Jung M; Park J; Cho EK; Lee WK; Chung M; Kim HS; Lee JH; Shin DB
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):277-84. PubMed ID: 22752217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy.
    Shitara K; Chin K; Yoshikawa T; Katai H; Terashima M; Ito S; Hirao M; Yoshida K; Oki E; Sasako M; Emi Y; Tsujinaka T
    Gastric Cancer; 2017 Jan; 20(1):175-181. PubMed ID: 26626800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of postoperative radiotherapy concurrent with S-1 in patients with gastric cancer.
    Qiu M; Peng XC; Bi F; Wang X; Li Q; Xu F; Li ZP; Shen YL; Liu JY; Zhao YQ; Cao D; Gou HF; Yang Y; Chen Y; Yi C
    Med Oncol; 2015 Jul; 32(7):191. PubMed ID: 26025485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.